Alto Neuroscience (ANRO) Long-Term Debt Issuances (2024 - 2025)
Alto Neuroscience (ANRO) posted Long-Term Debt Issuances of -$18.9 million for Q3 2025, down 196.19% sequentially from $19.7 million in Q1 2025, and down 1556.77% YoY from $1.3 million in Q3 2024.
Alto Neuroscience (ANRO) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Alto Neuroscience has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$18.9 million in Q3 2025.
- Quarterly Long-Term Debt Issuances fell 1556.77% year-over-year to -$18.9 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 184.97% YoY) and the FY2025 annual result came in at $750000.0, changed N/A from the prior year.
- Long-Term Debt Issuances slipped to -$18.9 million in Q3 2025 per ANRO's latest filing, from $19.7 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $19.7 million in Q1 2025 and troughed at -$18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -18.94 Mn |
| Sep 30, 2025 | -18.94 Mn |
| Mar 31, 2025 | 19.69 Mn |
| Mar 31, 2025 | 19.69 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |